Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$8.61 +2.3%	$9.79	$7.35 ▼ $13.70	$2.60B	0.11	157,114 shs	147,157 shs
ANAB AnaptysBio	$27.15 +1.1%	$22.69	$12.21 ▼ $41.31	$797.49M	-0.27	647,879 shs	126,000 shs
CRNX Crinetics Pharmaceuticals	$33.00 +3.4%	$30.98	$24.10 ▼ $62.53	$3.09B	0.25	816,105 shs	147,928 shs
HCM HUTCHMED	$17.45 +1.9%	$15.03	$11.51 ▼ $21.50	$3.04B	0.52	91,711 shs	9,769 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	+0.12%	-3.66%	-9.85%	+1.57%	-30.64%
ANAB AnaptysBio	+0.86%	+4.35%	+12.38%	+30.71%	-22.10%
CRNX Crinetics Pharmaceuticals	+0.22%	-1.33%	+2.24%	+4.87%	-41.98%
HCM HUTCHMED	+3.44%	+5.09%	+2.03%	+24.49%	-8.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVO Alvotech	2.7024 of 5 stars	3.5	2.0	0.0	2.6	0.0	1.9
ANAB AnaptysBio	1.6677 of 5 stars	3.4	0.0	0.0	1.5	2.5	0.6
CRNX Crinetics Pharmaceuticals	3.4482 of 5 stars	3.4	0.0	3.7	2.5	2.5	0.0
HCM HUTCHMED	1.6162 of 5 stars	2.0	3.0	0.0	2.5	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	3.00	Buy	$18.00	109.06% Upside
ANAB AnaptysBio	2.80	Moderate Buy	$42.38	56.11% Upside
CRNX Crinetics Pharmaceuticals	2.80	Moderate Buy	$69.50	110.61% Upside
HCM HUTCHMED	2.00	Hold	$19.00	8.88% Upside

Current Analyst Ratings Breakdown

Latest ANAB, CRNX, ALVO, and HCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	CRNX Crinetics Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$36.00
6/27/2025	CRNX Crinetics Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/4/2025	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$22.00 ➝ $38.00
5/29/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
5/28/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $90.00
5/13/2025	HCM HUTCHMED	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/6/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $54.00
5/1/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$585.60M	4.43	N/A	N/A	($1.37) per share	-6.28
ANAB AnaptysBio	$91.28M	8.74	N/A	N/A	$2.33 per share	11.65
CRNX Crinetics Pharmaceuticals	$1.04M	2,970.86	N/A	N/A	$14.29 per share	2.31
HCM HUTCHMED	$630.20M	4.83	$0.30 per share	57.65	$4.43 per share	3.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	-$231.86M	$0.37	23.31	43.05	N/A	16.42%	-36.37%	12.70%	8/21/2025 (Estimated)
ANAB AnaptysBio	-$145.23M	-$4.85	N/A	N/A	N/A	-125.70%	-282.47%	-30.79%	8/4/2025 (Estimated)
CRNX Crinetics Pharmaceuticals	-$298.41M	-$3.82	N/A	N/A	N/A	N/A	-30.95%	-28.12%	8/6/2025 (Estimated)
HCM HUTCHMED	$37.73M	N/A	0.00	11.95	N/A	N/A	N/A	N/A	8/7/2025 (Estimated)

Latest ANAB, CRNX, ALVO, and HCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRNX Crinetics Pharmaceuticals	-$1.13	N/A	N/A	N/A	$0.52 million	N/A
8/4/2025	Q2 2025	ANAB AnaptysBio	-$1.47	N/A	N/A	N/A	$11.55 million	N/A
5/8/2025	Q1 2025	CRNX Crinetics Pharmaceuticals	-$0.99	-$1.04	-$0.05	-$1.04	$0.10 million	$0.36 million
5/7/2025	Q1 2025	ALVO Alvotech	-$0.17	$0.35	+$0.52	$0.35	N/A	N/A
5/5/2025	Q1 2025	ANAB AnaptysBio	-$1.30	-$1.28	+$0.02	-$1.28	$15.27 million	$27.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.73	1.19
ANAB AnaptysBio	N/A	8.25	8.25
CRNX Crinetics Pharmaceuticals	N/A	22.53	22.53
HCM HUTCHMED	0.08	2.83	2.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
ANAB AnaptysBio	N/A
CRNX Crinetics Pharmaceuticals	98.51%
HCM HUTCHMED	8.82%

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	0.46%
ANAB AnaptysBio	33.50%
CRNX Crinetics Pharmaceuticals	4.60%
HCM HUTCHMED	3.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,032	301.48 million	300.10 million	Not Optionable
ANAB AnaptysBio	100	29.38 million	19.54 million	Optionable
CRNX Crinetics Pharmaceuticals	210	93.63 million	89.32 million	Optionable
HCM HUTCHMED	1,811	174.42 million	168.14 million	Not Optionable

ANAB, CRNX, ALVO, and HCM Headlines

Recent News About These Companies

HUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading Volume - What's Next?

July 9, 2025 | marketbeat.com

HUTCHMED to Announce 2025 Half-Year Financial Results

July 3, 2025 | globenewswire.com

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

June 30, 2025 | globenewswire.com

HUTCHMED (NASDAQ:HCM) Upgraded by Wall Street Zen to "Strong-Buy" Rating

June 27, 2025 | marketbeat.com

HUTCHMED (China) Limited (HCM.L) - Yahoo Finance

June 26, 2025 | nz.finance.yahoo.com

HUTCHMED (China) Limited (HCM) - Yahoo Finance

June 26, 2025 | au.finance.yahoo.com

How Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52% - Nasdaq

June 25, 2025 | nasdaq.com

How Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52%

June 23, 2025 | zacks.com

Paycom Software: Automating Payroll And HCM Solutions; Initiate With 'Buy'

June 22, 2025 | seekingalpha.com

HUTCHMED (NASDAQ:HCM) Shares Gap Down - Time to Sell?

June 17, 2025 | marketbeat.com

Hutchmed introduces new share options and LTIP awards

June 11, 2025 | uk.investing.com

HUTCHMED Grants Share Options and LTIP Awards to Boost Talent Retention

June 10, 2025 | tipranks.com

Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?

June 5, 2025 | zacks.com

China accepts NDA for sintilimab and fruquintinib combo in kidney cancer

June 4, 2025 | msn.com

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma

June 4, 2025 | prnewswire.com

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

June 4, 2025 | globenewswire.com

HUTCHMED’s SACHI Phase III Study Shows Promising Results for Lung Cancer Treatment

June 1, 2025 | tipranks.com

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

June 1, 2025 | globenewswire.com

HUTCHMED to Present Promising Oncology Data at 2025 ASCO Meeting

May 22, 2025 | tipranks.com

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

May 22, 2025 | globenewswire.com

HUTCHMED Successfully Passes All Resolutions at 2025 AGM

May 13, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB, CRNX, ALVO, and HCM Company Descriptions

Alvotech NASDAQ:ALVO

$8.61 +0.19 (+2.26%)

As of 12:41 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

AnaptysBio NASDAQ:ANAB

$27.14 +0.29 (+1.06%)

As of 12:41 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Crinetics Pharmaceuticals NASDAQ:CRNX

$33.00 +1.10 (+3.45%)

As of 12:41 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

HUTCHMED NASDAQ:HCM

$17.45 +0.32 (+1.87%)

As of 12:39 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time